Skip to content
lifestyle.xbode.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Attralus, Inc
Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
August 12, 2026
Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
June 4, 2026